There are more than 100
different cancer diseases. Cancer is the leading cause of death in the United
States, and according to National Cancer Institute (NCI) estimates, half of all
U.S. males and one-third of all U.S. females will develop cancer in their lifetime.
While soft tissue sarcoma is a very rare form of cancer, the NCI reports that
in 2011 nearly 11,000 new cases of soft tissue sarcomas were diagnosed in the
U.S. and that approximately 3,900 deaths were caused by these cancers.
CytRx is a biopharmaceutical
R&D company focused on the development of its cancer-centered clinical
pipeline, which includes aldoxorubicin, the company’s improved version of the
widely used chemotherapeutic agent doxorubicin. In a recent phase 2b study
head-to-head between the drugs, aldoxorubicin met primary endpoints and
demonstrated its superiority over doxorubicin. Furthermore, aldoxorubicin was
found to be safe and well-tolerated with no treatment-related deaths.
The results were huge. The
outcome of the trial triggered a triple-digit rally in CytRx stock as the
investment community picked-up on the statistically significant results and
aldoxorubicin’s potential to open the door for additional therapeutic
applications.
Aldoxorubicin will soon
undergo a phase 3 pivotal trial under a special protocol assessment (SPA) as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy.
The U.S. Food and Drug
Administration granted the drug candidate orphan drug designation for the
treatment of patients with soft tissue sarcomas and pancreatic cancer. This
designation is granted to therapeutics being developed for the treatment of
rare diseases that affect fewer than 200,000 people in the United States. With
this position, CytRx has a seven-year marketing exclusivity period, clinical
protocol assistance with the FDA, and access to federal grants and tax credits.
With high expectations for
2014, CytRx appears to be well-positioned to revolutionize the unmet medical
needs in cancer, starting with soft tissue sarcoma.
For more information visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
